Details

Autor(en) / Beteiligte

• Munafò, Andrea Raffaele
• Scotti, Andrea
• Estévez-Loureiro, Rodrigo
• Adamo, Marianna
• Hernàndez, Antonio Portolés
• Peregrina, Estefanìa Fernàndez
• Gutierrez, Lola
• Taramasso, Maurizio
• Fam, Neil P.
• Ho, Edwin C.
• Asgar, Anita
• Vitrella, Giancarlo
• Raineri, Claudia
• Chizzola, Giuliano
• Pezzola, Elisa
• Le Ruz, Robin
• Montalto, Claudio
• Oreglia, Jacopo A.
• Fraccaro, Chiara
• Giannini, Cristina
• Fiorelli, Francesca
• Rubbio, Antonio Popolo
• Ooms, J.F.
• Compagnone, Miriam
• Marcelli, Chiara
• Maffeo, Diego
• Bettari, Luca
• Fürholz, Monika
• Arzamendi, Dabit
• Guerin, Patrice
• Tamburino, Corrado
• Petronio, A. Sonia
• Grasso, Carmelo
• Agricola, Eustachio
• Van Mieghem, Nicolas M.
• Tarantini, Giuseppe
• Praz, Fabien
• Pascual, Isaac
• Potena, Luciano
• Colombo, Antonio
• Maisano, Francesco
• Metra, Marco
• Margonato, Alberto
• Crimi, Gabriele
• Saia, Francesco
• Godino, Cosmo

Titel

2-year outcomes of MitraClip as a bridge to heart transplantation: The international MitraBridge registry

Ist Teil von

• International journal of cardiology, 2023-11, Vol.390, p.131139-131139, Article 131139

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• In the first report from the MitraBridge registry, MitraClip as a bridge to heart transplantation (HTx) proved to be at 1-year an effective treatment strategy for 119 patients with advanced heart failure (HF) who were potential candidates for HTx. We aimed to determine if benefits of MitraClip procedure as a bridge-to-transplant persist up to 2-years. By the end of the enrollment period, a total of 153 advanced HF patients (median age 59 years, left ventricular ejection fraction 26.9 ± 7.7%) with significant secondary mitral regurgitation, who were potential candidates for HTx and were treated with MitraClip as a bridge-to-transplant strategy, were included in the MitraBridge registry. The primary endpoint was the 2-year composite adverse events rate of all-cause death, first hospitalization for HF, urgent HTx or LVAD implantation. Procedural success was achieved in 89.5% of cases. Thirty-day mortality was 0%. At 2-year, Kaplan-Meier estimates of freedom from primary endpoint was 47%. Through 24 months, the annualized rate of HF rehospitalization per patient-year was 44%. After an overall median follow-up time of 26 (9–52) months, elective HTx was successfully performed in 30 cases (21%), 19 patients (13.5%) maintained or obtained the eligibility for transplant, and 32 patients (22.5%) no longer had an indication for HTx because of significant clinical improvement. After 2-years of follow-up, the use of MitraClip as a bridge-to-transplant was confirmed as an effective strategy, allowing elective HTx or eligibility for transplant in one third of patients, and no more need for transplantation in 22.5% of cases. •Advanced heart failure patients often need bridging therapies to heart transplant.•Secondary mitral regurgitation negatively affects their prognosis.•MitraClip used as a bridge to heart transplant strategy.•MitraClip is a safe and effective procedure in this advanced scenario.•It could guarantee safe access to or eligibility for transplant.